Tumor Immunotherapy and Microbiome: From Bench-to-Bedside Applications

Abstract

Cancer immunotherapy has emerged as a transformative therapeutic strategy that harnesses the immune system to combat malignant tumors, overcoming critical limitations such as the nonspecific cytotoxicity of conventional chemotherapy and radiotherapy and drug resistance arising from target mutations in targeted therapies. Growing evidence demonstrates that the human microbiome plays a pivotal role in modulating immune responses and influencing the efficacy of immunotherapeutic interventions. Although the impact is increasingly recognized, the molecular mechanisms and translational potential of microbiome-based strategies remain incompletely explored. This review systematically elucidates how microorganisms from distinct anatomical sites (including bacteria, fungi, and viruses residing in the gut, oral cavity, skin, respiratory tract, and urogenital tract) and intratumoral microbes modulate the tumor immune microenvironment through metabolites, immune cell priming, and antigen mimicry. Furthermore, we discuss how specific microbial signatures predict responses to immune checkpoint inhibitors (ICIs) and CAR-T cell therapy, and highlight emerging interventional strategies, including fecal microbiome transplantation (FMT), probiotics, and engineered bacteria, that demonstrate synergistic effects with immunotherapy in preclinical and clinical settings. By integrating mechanistic insights with translational advances, this review provides a comprehensive scientific foundation for microbiome-based precision immunotherapy, aimed at improving patient survival outcomes and reducing treatment-related adverse events.

Keywords

cancer / immune checkpoint inhibitors / immunotherapy / microbiome / tumor microenvironment

References

[1] C. Fang, G. Xiao, T. Wang, et al., “Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy,” Research (Washington, DC) 6 (2023): 0108.

[2] Q. Cao, R. Xue, and N. Zhang, “Th1 Cells Inducing IFNγ Response Improves Immunotherapy Efficacy in Gastric Cancer,” Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu 35 (2023): 299–315.

[3] L. Yu, K. Huang, Y. Liao, L. Wang, G. Sethi, and Z. Ma, “Targeting Novel Regulated Cell Death: Ferroptosis, Pyroptosis and Necroptosis in Anti-PD-1/PD-L1 Cancer Immunotherapy,” Cell Proliferation 57 (2024): e13644.

[4] Z. Zhou, Y. Chen, Y. Ba, et al., “Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non-Viral CAR-NK Cell Engineering,” Cell Proliferation 58 (2025): e13791.

[5] S. Cheng, B. Li, J. Yu, and L. Wang, “Update of Latest Data for Combined Therapy for Esophageal Cancer Using Radiotherapy and Immunotherapy: A Focus on Efficacy, Safety, and Biomarkers,” Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu 35 (2023): 483–500.

[6] J. Liu, W. Liu, Y. Wan, and W. Mao, “Crosstalk Between Exercise and Immunotherapy: Current Understanding and Future Directions,” Research (Washington, DC) 7 (2024): 0360.

[7] A. Lin, K. Zheng, A. Jiang, et al., “The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events,” Med Research (2025): 1–37.

[8] D.-R. Wang, X.-L. Wu, and Y.-L. Sun, “Therapeutic Targets and Biomarkers of Tumor Immunotherapy: Response Versus Non-Response,” Signal Transduction and Targeted Therapy 7 (2022): 331.

[9] A. J. Korman, K. S. Peggs, and J. P. Allison, “Checkpoint Blockade in Cancer Immunotherapy,” Advances in Immunology 90 (2006): 297–339.

[10] M. Khasraw, D. A. Reardon, M. Weller, and J. H. Sampson, “PD-1 Inhibitors: Do They Have a Future in the Treatment of Glioblastoma?,” Clinical Cancer Research Official American Journal of Cancer Research 26 (2020): 5287–5296.

[11] A. Lin, Z. Qiu, J. Zhang, and P. Luo, “Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient With Bladder Cancer,” Frontiers in Immunology 12 (2021): 630773.

[12] W. Huang, A. Lin, P. Luo, et al., “EPHA5 Mutation Predicts the Durable Clinical Benefit of Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma,” Cancer Gene Therapy 28 (2021): 864–874.

[13] A. Lin, P. Ye, Z. Li, et al., “Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment,” Research (Washington, DC) 8 (2025): 0723.

[14] S. Zhao, H. Zhao, W. Yang, and L. Zhang, “The Next Generation of Immunotherapies for Lung Cancers,” Nature Reviews Clinical Oncology 22 (2025): 592–616.

[15] J.-W. Cui, Y. Li, Y. Yang, et al., “Tumor Immunotherapy Resistance: Revealing the Mechanism of PD-1/PD-L1-Mediated Tumor Immune Escape,” Biomedicine & Pharmacotherapy 171 (2024): 116203.

[16] D. S. Vinay, E. P. Ryan, G. Pawelec, et al., “Immune Evasion in Cancer: Mechanistic Basis and Therapeutic Strategies,” Seminars in Cancer Biology 35 (2015): S185–S198.

[17] Y. Niu, A. Lin, P. Luo, et al., “Prognosis of Lung Adenocarcinoma Patients with NTRK3 Mutations to Immune Checkpoint Inhibitors,” Frontiers in Pharmacology 11 (2020): 1213.

[18] R. Yi, A. Lin, M. Cao, A. Xu, P. Luo, and J. Zhang, “ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment,” Frontiers in Genetics 11 (2020): 933.

[19] S. Peng, A. Lin, A. Jiang, et al., “CTLs Heterogeneity and Plasticity: Implications for Cancer Immunotherapy,” Molecular Cancer 23 (2024): 58.

[20] G. Morad, B. A. Helmink, P. Sharma, and J. A. Wargo, “Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade,” Cell 184 (2021): 5309–5337.

[21] P. Zhang, G. Zhang, and X. Wan, “Challenges and New Technologies in Adoptive Cell Therapy,” Journal of Hematology & Oncology 16 (2023): 97.

[22] L. Zhong, L. Gan, B. Wang, et al., “Hyperacute Rejection-Engineered Oncolytic Virus for Interventional Clinical Trial in Refractory Cancer Patients,” Cell 188 (2025): 1119-1136. e23.

[23] L. Drew, “How Does a Cancer Vaccine Work?,” Nature 627 (2024): S34–S35.

[24] J. Shen, R. Hu, A. Lin, et al., “Characterization of Second Primary Malignancies Post CAR T-Cell Therapy: Real-World Insights From the Two Global Pharmacovigilance Databases of FAERS and VigiBase,” EClinicalMedicine 73 (2024): 102684.

[25] G. Li, Y. Wan, A. Jiao, et al., “Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments,” MedResearch 1 (2025): 62–102.

[26] C. Lin, W. Teng, Y. Tian, S. Li, N. Xia, and C. Huang, “Immune Landscape and Response to Oncolytic Virus-Based Immunotherapy,” Frontiers in Medicine 18 (2024): 411–429.

[27] Oncolytic Viral Therapy Is Feasible in Diffuse Intrinsic Pontine Glioma. Cancer Discover 12 (2022): 2012.

[28] P. Luo, A. Lin, K. Li, T. Wei, and J. Zhang, “DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing,” Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer 14 (2019): e276–e279.

[29] N. Zhang, H. Zhang, Z. Liu, et al., “An Artificial Intelligence Network-Guided Signature for Predicting Outcome and Immunotherapy Response in Lung Adenocarcinoma Patients Based on 26 Machine Learning Algorithms,” Cell Proliferation 56 (2023): e13409.

[30] Y. Huang, Z. Tian, and J. Bi, “Intracellular Checkpoints for NK Cell Cancer Immunotherapy,” Frontiers in Medicine 18 (2024): 763–777.

[31] J. Li, J. Peng, J. Wang, and Z. Chen, “The Dual Role of Exosomes in the Tumor Microenvironment: From Pro-Tumorigenic Signaling to Immune Modulation,” Med Research 1 (2025): 257–284.

[32] P. Gotwals, S. Cameron, D. Cipolletta, V. Cremasco, A. Crystal, and B. Hewes, “Prospects for Combining Targeted and Conventional Cancer Therapy With Immunotherapy,” Nature Reviews Cancer 17 (2017): 286–301.

[33] M. Fillon, “Adding Immunotherapy to Chemotherapy Improves Survival for Endometrial Cancer Patients,” CA: A Cancer Journal for Clinicians 73 (2023): 445–447.

[34] E. Martinelli and D. Ciardiello, “Combining Chemotherapy and Immunotherapy for Advanced Anal Cancer: Are We Ready?,” Lancet Oncology 25 (2024): 416–417.

[35] Z. Ma, T. Zuo, N. Frey, and A. Y. Rangrez, “A Systematic Framework for Understanding the Microbiome in Human Health and Disease: From Basic Principles to Clinical Translation,” Signal Transduction and Targeted Therapy 9 (2024): 237.

[36] K. Ratiner, D. Ciocan, S. K. Abdeen, and E. Elinav, “Utilization of the Microbiome in Personalized Medicine,” Nature Reviews Microbiology 22 (2024): 291–308.

[37] S. V. Lynch and O. Pedersen, “The Human Intestinal Microbiome in Health and Disease,” New England Journal of Medicine 375 (2016): 2369–2379.

[38] L. A. Ahmed and K. F. Al-Massri, “Gut Microbiota Modulation for Therapeutic Management of Various Diseases: A New Perspective Using Stem Cell Therapy,” Current Molecular Pharmacology 16 (2023): 43–59.

[39] R. Mauceri, M. Coppini, D. Vacca, et al., “No Clear Clustering Dysbiosis From Salivary Microbiota Analysis by Long Sequencing Reads in Patients Affected by Oral Squamous Cell Carcinoma: A Single Center Study,” Cancers 15 (2023): 4211.

[40] N. Madhusudhan, M. R. Pausan, B. Halwachs, et al., “Molecular Profiling of Keratinocyte Skin Tumors Links Staphylococcus aureus Overabundance and Increased Human β-Defensin-2 Expression to Growth Promotion of Squamous Cell Carcinoma,” Cancers 12 (2020): 541.

[41] A. J. K. Kombe, S. Zoa-Assoumou, G.-A. Bounda, F.-A. Nsole-Biteghe, T. Jin, and A. A. Zouré, “Advances in Etiopathological Role and Control of HPV in Cervical Cancer Oncogenesis,” Frontiers in Bioscience-Landmark Edition 28 (2023): 245.

[42] S. Miao and H. Qiu, “The Microbiome in the Pathogenesis of Lung Cancer: The Role of Microbiome in Lung Cancer Pathogenesis,” APMIS Acta Pathologica, Microbiologica, et Immunologica Scandinavica 132 (2024): 68–80.

[43] C. Xuan, J. M. Shamonki, A. Chung, et al., “Microbial Dysbiosis Is Associated With Human Breast Cancer,” PLoS ONE 9 (2014): e83744.

[44] Y. Chen, L. Yang, Y. Huang, et al., “Intratumoral Microbiota Predicts the Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer,” Journal for ImmunoTherapy of Cancer 13 (2025): e010365.

[45] J. Chen, Y. Gao, Y. Chen, et al., “Identification and Validation of Intratumoral Microbiome Associated With Sensitization to Immune Checkpoint Inhibitors,” Cell Reports Medicine 6 (2025): 102306.

[46] W. Mou, Z. Deng, L. Zhu, et al., “Intratumoral Mycobiome Heterogeneity Influences the Tumor Microenvironment and Immunotherapy Outcomes in Renal Cell Carcinoma,” Science Advances 11 (2025): eadu1727.

[47] J. Liu and Y. Zhang, “Intratumor Microbiome in Cancer Progression: Current Developments, Challenges and Future Trends,” Biomarker Research 10 (2022): 37.

[48] M. Wang, F. Yu, and P. Li, “Intratumor Microbiota in Cancer Pathogenesis and Immunity: From Mechanisms of Action to Therapeutic Opportunities,” Frontiers in Immunology 14 (2023): 1269054.

[49] G. Ameya and D. J. Birri, “The Molecular Mechanisms of Virus-Induced Human Cancers,” Microbial Pathogenesis 183 (2023): 106292.

[50] Z. Gao, A. Jiang, Z. Li, et al., “Heterogeneity of Intratumoral Microbiota Within the Tumor Microenvironment and Relationship to Tumor Development,” Med Research 1 (2025): 32–61.

[51] M. Fulde and M. W. Hornef, “Maturation of the Enteric Mucosal Innate Immune System During the Postnatal Period,” Immunological Reviews 260 (2014): 21–34.

[52] H. Huang, W. Zhong, X. Wang, et al., “The Role of Gastric Microecological Dysbiosis in Gastric Carcinogenesis,” Frontiers in Microbiology 14 (2023): 1218395.

[53] M. Hilmi, M. Kamal, S. Vacher, et al., “Intratumoral Microbiome Is Driven by Metastatic Site and Associated With Immune Histopathological Parameters: An Ancillary Study of the SHIVA Clinical Trial,” European Journal of Cancer (Oxford, England: 1990) 183 (2023): 152–161.

[54] E. Riquelme, Y. Zhang, L. Zhang, et al., “Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes,” Cell 178 (2019): 795–806.e12.

[55] S. Židovec Lepej, M. Matulić, P. Gršković, M. Pavlica, L. Radmanić, and P. Korać, “miRNAs: EBV Mechanism for Escaping Host's Immune Response and Supporting Tumorigenesis,” Pathogens (Basel, Switzerland) 9 (2020): 353.

[56] P. Yang, G. J. Markowitz, and X.-F. Wang, “The Hepatitis B Virus-Associated Tumor Microenvironment in Hepatocellular Carcinoma,” National Science Review 1 (2014): 396–412.

[57] L. Liu, Y. Xie, H. Yang, et al., “HPVTIMER: A Shiny Web Application for Tumor Immune Estimation in Human Papillomavirus-Associated Cancers,” Imeta 2 (2023): e130.

[58] M. F. Chevalier, S. Trabanelli, J. Racle, et al., “ILC2-Modulated T Cell-to-MDSC Balance Is Associated With Bladder Cancer Recurrence,” Journal of Clinical Investigation 127 (2017): 2916–2929.

[59] S. K. Mohanty, S. K. Mishra, M. B. Amin, A. Agaimy, and F. Fuchs, “Role of Surgical Pathologist for the Detection of Immuno-Oncologic Predictive Factors in Non-Small Cell Lung Cancers,” Advances in Anatomic Pathology 30 (2023): 174–194.

[60] S. J. Blake, Y. Wolf, B. Boursi, and D. J. Lynn, “Role of the Microbiota in Response to and Recovery From Cancer Therapy,” Nature Reviews Immunology 24 (2024): 308–325.

[61] S. Kalaora, A. Nagler, D. Nejman, et al., “Identification of Bacteria-Derived HLA-Bound Peptides in Melanoma,” Nature 592 (2021): 138–143.

[62] M.-W. Chung, M.-J. Kim, E. J. Won, et al., “Gut Microbiome Composition Can Predict the Response to nivolumab in Advanced Hepatocellular Carcinoma Patients,” World Journal of Gastroenterology 27 (2021): 7340–7349.

[63] D. Liu, L. Yu, H. Rong, L. Liu, and J. Yin, “Engineering Microorganisms for Cancer Immunotherapy,” Advanced Healthcare Materials 13 (2024): e2304649.

[64] D. J. Pinato, D. Gramenitskaya, D. M. Altmann, et al., “Antibiotic Therapy and Outcome From Immune-Checkpoint Inhibitors,” Journal for ImmunoTherapy of Cancer 7 (2019): 287.

[65] J. Raber and T. J. Sharpton, “Gastrointestinal Dysfunction in Neurological and Neurodegenerative Disorders,” Seminars in Neurology 43 (2023): 634–644.

[66] P. Spanogiannopoulos, E. N. Bess, R. N. Carmody, and P. J. Turnbaugh, “The Microbial Pharmacists Within Us: A Metagenomic View of Xenobiotic Metabolism,” Nature Reviews Microbiology 14 (2016): 273–287.

[67] F. Bäckhed, R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon, “Host-Bacterial Mutualism in the Human Intestine,” Science 307 (2005): 1915–1920.

[68] T. Yatsunenko, F. E. Rey, M. J. Manary, et al., “Human Gut Microbiome Viewed Across Age and Geography,” Nature 486 (2012): 222–227.

[69] J. Doré and H. Blottière, “The Influence of Diet on the Gut Microbiota and Its Consequences for Health,” Current Opinion in Biotechnology 32 (2015): 195–199.

[70] A. C. Gomes, C. Hoffmann, and J. F. Mota, “The Human Gut Microbiota: Metabolism and Perspective in Obesity,” Gut Microbes 9 (2018): 308–325.

[71] P. B. Eckburg, E. M. Bik, C. N. Bernstein, et al., “Diversity of the Human Intestinal Microbial Flora,” Science 308 (2005): 1635–1638.

[72] J. C. Pérez, “Fungi of the Human Gut Microbiota: Roles and Significance,” International Journal of Medical Microbiology IJMM 311 (2021): 151490.

[73] M. Matijašić, T. Meštrović, H. Č. Paljetak, M. Perić, A. Barešić, and D. Verbanac, “Gut Microbiota Beyond Bacteria-Mycobiome, Virome, Archaeome, and Eukaryotic Parasites in IBD,” International Journal of Molecular Sciences 21 (2020): 2668.

[74] A. N. Shkoporov, A. G. Clooney, T. D. S. Sutton, et al., “The Human Gut Virome Is Highly Diverse, Stable, and Individual Specific,” Cell Host & Microbe 26 (2019): 527–541.e5.

[75] P. D. Scanlan, F. Shanahan, and J. R. Marchesi, “Human Methanogen Diversity and Incidence in Healthy and Diseased Colonic Groups Using mcrA Gene Analysis,” BMC Microbiology 8 (2008): 79.

[76] Y. Situ, P. Zhang, C. Zhang, et al., “The Metabolic Dialogue Between Intratumoural Microbes and Cancer: Implications for Immunotherapy,” EBioMedicine 115 (2025): 105708.

[77] A. Nishida, R. Inoue, O. Inatomi, S. Bamba, Y. Naito, and A. Andoh, “Gut Microbiota in the Pathogenesis of Inflammatory Bowel Disease,” Clinical Journal of Gastroenterology 11 (2018): 1–10.

[78] N. Li, Z. Dai, Z. Wang, et al., “Gut Microbiota Dysbiosis Contributes to the Development of Chronic Obstructive Pulmonary Disease,” Respiratory Research 22 (2021): 274.

[79] X. Fan, Y. Jin, G. Chen, X. Ma, and L. Zhang, “Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer,” Digestion 102 (2021): 508–515.

[80] L. V. Hooper, D. R. Littman, and A. J. Macpherson, “Interactions Between the Microbiota and the Immune System,” Science 336 (2012): 1268–1273.

[81] D. Bouskra, C. Brézillon, M. Bérard, et al., “Lymphoid Tissue Genesis Induced by Commensals Through NOD1 Regulates Intestinal Homeostasis,” Nature 456 (2008): 507–510.

[82] M. Hu, D. Eviston, P. Hsu, et al., “Decreased Maternal Serum Acetate and Impaired Fetal Thymic and Regulatory T Cell Development in Preeclampsia,” Nature Communications 10 (2019): 3031.

[83] J. Shen, W. Liang, R. Zhao, et al., “Cross-Tissue Multi-Omics Analyses Reveal the Gut Microbiota's Absence Impacts Organ Morphology, Immune Homeostasis, Bile Acid and Lipid Metabolism,” Imeta 4 (2025): e272.

[84] A. Cebula, M. Seweryn, G. A. Rempala, et al., “Thymus-Derived Regulatory T Cells Contribute to Tolerance to Commensal Microbiota,” Nature 497 (2013): 258–262.

[85] K. Nagashima, “Blockbuster T Cells in the Gut: A High-Resolution View of Immune Modulation by the Gut Microbiome Is Presented,” Science 385 (2024): 36–37.

[86] D. F. Zegarra-Ruiz, D. V. Kim, K. Norwood, et al., “Thymic Development of Gut-Microbiota-Specific T Cells,” Nature 594 (2021): 413–417.

[87] K. Minton, “Immune Checkpoint Blockade Breaches the Mucosal Firewall to Induce Gut Microbiota Translocation,” Nature Reviews Immunology 23 (2023): 269.

[88] Z. Yang, Z. Lin, Y. You, et al., “Gut Microbiota-Derived Hyocholic Acid Enhances Type 3 Immunity and Protects against Salmonella enterica Serovar Typhimurium in Neonatal Rats,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12 (2025): e2412071.

[89] X. Kang, H. C.-H. Lau, and J. Yu, “Modulating Gut Microbiome in Cancer Immunotherapy: Harnessing Microbes to Enhance Treatment Efficacy,” Cell Reports Medicine 5 (2024): 101478.

[90] P. López, I. González-Rodríguez, B. Sánchez, M. Gueimonde, A. Margolles, and A. Suárez, “Treg-Inducing Membrane Vesicles From Bifidobacterium bifidum LMG13195 as Potential Adjuvants in Immunotherapy,” Vaccine 30 (2012): 825–829.

[91] J. H. Choi, C. M. Moon, T.-S. Shin, et al., “Lactobacillus paracasei-Derived Extracellular Vesicles Attenuate the Intestinal Inflammatory Response by Augmenting the Endoplasmic Reticulum Stress Pathway,” Experimental & Molecular Medicine 52 (2020): 423–437.

[92] N. Diaz-Garrido, J. Badia, and L. Baldomà, “Modulation of Dendritic Cells by Microbiota Extracellular Vesicles Influences the Cytokine Profile and Exosome Cargo,” Nutrients 14 (2022): 344.

[93] W. Yang and Y. Cong, “Gut Microbiota-Derived Metabolites in the Regulation of Host Immune Responses and Immune-Related Inflammatory Diseases,” Cellular & Molecular Immunology 18 (2021): 866–877.

[94] L. Jiang, Y. Hao, D. Han, W. Dong, A. Yang, and Z. Sun, “Gut Microbiota Dysbiosis Deteriorates Immunoregulatory Effects of Tryptophan via Colonic Indole and LBP/HTR2B-Mediated Macrophage Function,” ISME Journal 18 (2024): wrae166.

[95] E. T. Grant, A. Parrish, M. Boudaud, et al., “Dietary Fibers Boost Gut Microbiota-Produced B Vitamin Pool and Alter Host Immune Landscape,” Microbiome 12 (2024): 179.

[96] J. L. Round and S. K. Mazmanian, “Inducible Foxp3+ Regulatory T-cell Development by a Commensal Bacterium of the Intestinal Microbiota,” PNAS 107 (2010): 12204–12209.

[97] C. H. Kim, “Complex Regulatory Effects of Gut Microbial Short-Chain Fatty Acids on Immune Tolerance and Autoimmunity,” Cellular & Molecular Immunology 20 (2023): 341–350.

[98] R. Liu, J. Wang, Y. Liu, Y. Gao, and R. Yang, “Regulation of Gut Microbiota on Immune Cell Ferroptosis: A Novel Insight for Immunotherapy Against Tumor,” Cancer Letters 598 (2024): 217115.

[99] S. Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R. Medzhitov, “Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis,” Cell 118 (2004): 229–241.

[100] J. L. Kubinak, C. Petersen, W. Z. Stephens, et al., “MyD88 Signaling in T Cells Directs IgA-Mediated Control of the Microbiota to Promote Health,” Cell Host & Microbe 17 (2015): 153–163.

[101] S. Becattini, M. T. Sorbara, S. G. Kim, et al., “Rapid Transcriptional and Metabolic Adaptation of Intestinal Microbes to Host Immune Activation,” Cell Host & Microbe 29 (2021): 378–393.e5.

[102] A. Singh, S. V. Chandrasekar, V. T. Valappil, J. Scaria, and A. Ranjan, “Tumor Immunomodulation by Nanoparticle and Focused Ultrasound Alters Gut Microbiome in a Sexually Dimorphic Manner,” Theranostics 15 (2025): 216–232.

[103] I. Melo-Marques, S. M. Cardoso, and N. Empadinhas, “Bacterial Extracellular Vesicles at the Interface of Gut Microbiota and Immunity,” Gut Microbes 16 (2024): 2396494.

[104] M. Bemark, M. J. Pitcher, C. Dionisi, and J. Spencer, “Gut-Associated Lymphoid Tissue: A Microbiota-Driven Hub of B Cell Immunity,” Trends in Immunology 45 (2024): 211–223.

[105] J. A. Shim, J. H. Ryu, Y. Jo, and C. Hong, “The Role of Gut Microbiota in T Cell Immunity and Immune Mediated Disorders,” International Journal of Biological Sciences 19 (2023): 1178–1191.

[106] Z. Li, W. Xiong, Z. Liang, et al., “Critical Role of the Gut Microbiota in Immune Responses and Cancer Immunotherapy,” Journal of Hematology & Oncology 17 (2024): 33.

[107] R.-M. Berbers, F. L. Paganelli, J. M. van Montfrans, et al., “Gut Microbial Dysbiosis, IgA, and Enterococcus in Common Variable Immunodeficiency With Immune Dysregulation,” Microbiome 13 (2025): 12.

[108] H. Zhao, L. Wu, G. Yan, et al., “Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention,” Signal Transduction and Targeted Therapy 6 (2021): 263.

[109] P. Louis, G. L. Hold, and H. J. Flint, “The Gut Microbiota, Bacterial Metabolites and Colorectal Cancer,” Nature Reviews Microbiology 12 (2014): 661–672.

[110] S. V. Rajagopala, S. Vashee, L. M. Oldfield, et al., “The Human Microbiome and Cancer,” Cancer Prevention Research (Philadelphia, Pa) 10 (2017): 226–234.

[111] R. Caesar, V. Tremaroli, P. Kovatcheva-Datchary, P. D. Cani, and F. Bäckhed, “Crosstalk Between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation Through TLR Signaling,” Cell Metabolism 22 (2015): 658–668.

[112] K. J. O'Riordan, G. M. Moloney, L. Keane, G. Clarke, and J. F. Cryan, “The Gut Microbiota-Immune-Brain Axis: Therapeutic Implications,” Cell Reports Medicine 6 (2025): 101982.

[113] F. S. Gazzaniga and D. L. Kasper, “The Gut Microbiome and Cancer Response to Immune Checkpoint Inhibitors,” Journal of Clinical Investigation 135 (2025): e184321.

[114] V. Gopalakrishnan, C. N. Spencer, L. Nezi, et al., “Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients,” Science 359 (2018): 97–103.

[115] V. Matson, J. Fessler, R. Bao, et al., “The Commensal Microbiome Is Associated With Anti-PD-1 Efficacy in Metastatic Melanoma Patients,” Science 359 (2018): 104–108.

[116] B. Routy, E. Le Chatelier, L. Derosa, C. P. M. Duong, M. T. Alou, and R. Daillère, “Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors,” Science 359 (2018): 91–97.

[117] Y. Jin, H. Dong, L. Xia, et al., “The Diversity of Gut Microbiome Is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients with NSCLC,” Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer 14 (2019): 1378–1389.

[118] X. Zhu, M. Hu, X. Huang, et al., “Interplay Between Gut Microbial Communities and Metabolites Modulates Pan-Cancer Immunotherapy Responses,” Cell Metabolism 37, no. 4 (2025): 806–823.e6.

[119] X. Zhu, X. Huang, M. Hu, et al., “A Specific Enterotype Derived From Gut Microbiome of Older Individuals Enables Favorable Responses to Immune Checkpoint Blockade Therapy,” Cell Host & Microbe 32 (2024): 489–505.e5.

[120] A. Lin, A. Jiang, L. Huang, et al., “From Chaos to Order: Optimizing Fecal Microbiota Transplantation for Enhanced Immune Checkpoint Inhibitors Efficacy,” Gut Microbes 17 (2025): 2452277.

[121] C. C. Wong and J. Yu, “Gut Microbiota in Colorectal Cancer Development and Therapy,” Nature Reviews Clinical Oncology 20 (2023): 429–452.

[122] M. Vétizou, J. M. Pitt, R. Daillère, et al., “Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota,” Science 350 (2015): 1079–1084.

[123] Y. Lin, M. Xie, H. C.-H. Lau, et al., “Effects of Gut Microbiota on Immune Checkpoint Inhibitors in Multi-Cancer and as Microbial Biomarkers for Predicting Therapeutic Response,” Medical New York 6 (2025): 100530.

[124] D. Jia, Q. Wang, Y. Qi, et al., “Microbial Metabolite Enhances Immunotherapy Efficacy by Modulating T Cell Stemness in Pan-Cancer,” Cell 187 (2024): 1651–1665. e21.

[125] P. Sardar, B. S. Beresford-Jones, W. Xia, et al., “Gut Microbiota-Derived Hexa-Acylated Lipopolysaccharides Enhance Cancer Immunotherapy Responses,” Nature Microbiology 10 (2025): 795–807.

[126] D. Davar, A. K. Dzutsev, J. A. McCulloch, et al., “Fecal Microbiota Transplant Overcomes Resistance to Anti-PD-1 Therapy in Melanoma Patients,” Science 371 (2021): 595–602.

[127] K. A. Krautkramer, J. Fan, and F. Bäckhed, “Gut Microbial Metabolites as Multi-Kingdom Intermediates,” Nature Reviews Microbiology 19 (2021): 77–94.

[128] Y. He, L. Fu, Y. Li, et al., “Gut Microbial Metabolites Facilitate Anticancer Therapy Efficacy by Modulating Cytotoxic CD8+ T Cell Immunity,” Cell Metabolism 33 (2021): 988–1000.

[129] W. Deng, Z. Su, P. Liang, et al., “Single-Cell Immune Checkpoint Landscape of PBMCs Stimulated With Candida albicans,” Emerging Microbes & Infections 10 (2021): 1272–1283.

[130] S. Wurster, N. D. Albert, and D. P. Kontoyiannis, “Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model,” mSphere 7 (2022): e0081721.

[131] N. Guillot, B. Roméo, S. S. Manesh, et al., “Manipulating the Gut and Tumor Microbiota for Immune Checkpoint Inhibitor Therapy: From Dream to Reality,” Trends in Molecular Medicine 29 (2023): 897–911.

[132] J. R. Björk, L. A. Bolte, A. Maltez Thomas, et al., “Longitudinal Gut Microbiome Changes in Immune Checkpoint Blockade-Treated Advanced Melanoma,” Nature Medicine 30 (2024): 785–796.

[133] R. Liu, Y. Zou, W.-Q. Wang, et al., “Gut Microbial Structural Variation Associates With Immune Checkpoint Inhibitor Response,” Nature Communications 14 (2023): 7421.

[134] J. Shang, D. M. Del Valle, G. J. Britton, K. R. Mead, U. Rajpal, and A. Chen-Liaw, “Baseline Colitogenicity and Acute Perturbations of Gut Microbiota in Immunotherapy-Related Colitis,” Journal of Experimental Medicine 222 (2025): e20232079.

[135] Y. Wang, R. R. Jenq, J. A. Wargo, and S. S. Watowich, “Microbiome Influencers of Checkpoint Blockade-Associated Toxicity,” Journal of Experimental Medicine 220 (2023): e20220948.

[136] N. Chaput, P. Lepage, C. Coutzac, E. Soularue, K. Le Roux, and C. Monot, “Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With ipilimumab,” Annals of Oncolog Official European Journal of Medical and Clinical Oncology 28 (2017): 1368–1379.

[137] J. J. Mohiuddin, B. Chu, A. Facciabene, et al., “Association of Antibiotic Exposure with Survival and Toxicity in Patients with Melanoma Receiving Immunotherapy,” JNCI: Journal of the National Cancer Institute 113 (2021): 162–170.

[138] M. Smith, A. Dai, G. Ghilardi, et al., “Gut Microbiome Correlates of Response and Toxicity Following Anti-CD19 CAR T Cell Therapy,” Nature Medicine 28 (2022): 713–723.

[139] Y. Hu, J. Li, F. Ni, Z. Yang, X. Gui, and Z. Bao, “CAR-T Cell Therapy-Related Cytokine Release Syndrome and Therapeutic Response Is Modulated by the Gut Microbiome in Hematologic Malignancies,” Nature Communications 13 (2022): 5313.

[140] T. Giavridis, S. J. C. van der Stegen, J. Eyquem, M. Hamieh, A. Piersigilli, and M. Sadelain, “CAR T Cell-Induced Cytokine Release Syndrome Is Mediated by Macrophages and Abated by IL-1 Blockade,” Nature Medicine 24 (2018): 731–738.

[141] M. Luu, Z. Riester, A. Baldrich, et al., “Microbial Short-Chain Fatty Acids Modulate CD8+ T Cell Responses and Improve Adoptive Immunotherapy for Cancer,” Nature Communications 12 (2021): 4077.

[142] R. Prasad, A. Rehman, L. Rehman, et al., “Antibiotic-Induced Loss of Gut Microbiome Metabolic Output Correlates With Clinical Responses to CAR T-Cell Therapy,” Blood 145 (2025): 823–839.

[143] Z. DeFilipp and M. V. Maus, “Linking the Microbiome to CAR-T Cell Responses,” Nature Medicine 29 (2023): 785–786.

[144] L. Evgin, A. L. Huff, P. Wongthida, et al., “Oncolytic Virus-Derived Type I Interferon Restricts CAR T Cell Therapy,” Nature Communications 11 (2020): 3187.

[145] Z. Chang, X. Guo, X. Li, et al., “Bacterial Immunotherapy Leveraging IL-10R Hysteresis for both Phagocytosis Evasion and Tumor Immunity Revitalization,” Cell 188, no. 7 (2025): 1842–1857.e20.

[146] W. S. Lee, S. J. Lee, H. J. Lee, et al., “Oral Reovirus Reshapes the Gut Microbiome and Enhances Antitumor Immunity in Colon Cancer,” Nature Communications 15 (2024): 9092.

[147] P. Lombardi and D. J. Pinato, “Precision Targeting of the Gut Microbiome for Cancer Immunotherapy,” Cancer Discovery 14 (2024): 1140–1142.

[148] A. Montalban-Arques, E. Katkeviciute, P. Busenhart, et al., “Commensal Clostridiales Strains Mediate Effective Anti-Cancer Immune Response Against Solid Tumors,” Cell Host & Microbe 29 (2021): 1573–1588.e7.

[149] M. S. Thu and K. Pongpirul, “Response: Commentary: Human Gut, Breast, and Oral Microbiome in Breast Cancer: A Systematic Review and Meta-Analysis,” Frontiers in Oncology 13 (2023): 1279862.

[150] Z. Desalegn, A. Smith, M. Yohannes, et al., “Human Breast Tissue Microbiota Reveals Unique Microbial Signatures That Correlate With Prognostic Features in Adult Ethiopian Women With Breast Cancer,” Cancers 15 (2023): 4893.

[151] D. Hadzega, G. Minarik, M. Karaba, et al., “Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq,” International Journal of Molecular Sciences 22 (2021): 9058.

[152] D. Nejman, I. Livyatan, G. Fuks, et al., “The Human Tumor Microbiome Is Composed of Tumor Type-Specific Intracellular Bacteria,” Science 368 (2020): 973–980.

[153] O.-H. Kim, B.-Y. Choi, D. K. Kim, et al., “The Microbiome of Lung Cancer Tissue and Its Association With Pathological and Clinical Parameters,” American Journal of Cancer Research 12 (2022): 2350–2362.

[154] L. Narunsky-Haziza, G. D. Sepich-Poore, I. Livyatan, et al., “Pan-Cancer Analyses Reveal Cancer-Type-Specific Fungal Ecologies and Bacteriome Interactions,” Cell 185 (2022): 3789–3806.e17.

[155] A. B. Dohlman, J. Klug, M. Mesko, et al., “A Pan-Cancer Mycobiome Analysis Reveals Fungal Involvement in Gastrointestinal and Lung Tumors,” Cell 185 (2022): 3807–3822.e12.

[156] B. Aykut, S. Pushalkar, R. Chen, et al., “The Fungal Mycobiome Promotes Pancreatic Oncogenesis via Activation of MBL,” Nature 574 (2019): 264–267.

[157] H. Zur Hausen, “Papillomaviruses and Cancer: From Basic Studies to Clinical Application,” Nature Reviews Cancer 2 (2002): 342–350.

[158] R. J. Lamontagne, S. Bagga, and M. J. Bouchard, “Hepatitis B Virus Molecular Biology and Pathogenesis,” Hepatoma Research 2 (2016): 163–186.

[159] Q. Wu, L. Zhang, X. Xu, et al., “Hepatitis B Virus X Protein Is Stabilized by the Deubiquitinating Enzyme VCPIP1 in a Ubiquitin-Independent Manner by Recruiting the 26S Proteasome Subunit PSMC3,” Journal of Virology 96 (2022): e0061122.

[160] H. Yuan, R. Xu, S. Li, et al., “The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions,” MedComm 6 (2025): e70121.

[161] R. Dolcetti, A. Gloghini, A. Caruso, and A. Carbone, “A Lymphomagenic Role for HIV Beyond Immune Suppression?,” Blood 127 (2016): 1403–1409.

[162] Z.-M. Zheng, “Viral Oncogenes, Noncoding RNAs, and RNA Splicing in Human Tumor Viruses,” International Journal of Biological Sciences 6 (2010): 730–755.

[163] H. Hjalgrim, J. Askling, P. Sørensen, et al., “Risk of Hodgkin's Disease and Other Cancers After Infectious Mononucleosis,” JNCI: Journal of the National Cancer Institute 92 (2000): 1522–1528.

[164] L. J. Stanland and M. A. Luftig, “The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis,” Viruses 12 (2020): 1222.

[165] Y. Ma, H. Chen, H. Li, et al., “Intratumor Microbiome-Derived Butyrate Promotes Lung Cancer Metastasis,” Cell Reports Medicine 5 (2024): 101488.

[166] A. Alam, E. Levanduski, P. Denz, et al., “Fungal Mycobiome Drives IL-33 Secretion and Type 2 Immunity in Pancreatic Cancer,” Cancer Cell 40 (2022): 153–167.e11.

[167] J. Chen, “Signaling Pathways in HPV-Associated Cancers and Therapeutic Implications,” Reviews in Medical Virology 25, no. suppl. 1 (2015): 24–53.

[168] Y. Li, C. Zhang, A. Jiang, et al., “Potential Anti-Tumor Effects of Regulatory T Cells in the Tumor Microenvironment: A Review,” Journal of Translational Medicine 22 (2024): 293.

[169] S. M. Manohar, “At the Crossroads of TNF α Signaling and Cancer,” Current Molecular Pharmacology 17 (2024): e060923220758.

[170] S. Pol, A. Vallet-Pichard, and O. Hermine, “Extrahepatic Cancers and Chronic HCV Infection,” Nature Reviews Gastroenterology & Hepatology 15 (2018): 283–290.

[171] G. N. Pongas and J. C. Ramos, “HIV-Associated Lymphomas: Progress and New Challenges,” Journal of Clinical Medicine 11 (2022): 1447.

[172] M. Jiang, Z. Yang, J. Dai, et al., “Intratumor Microbiome: Selective Colonization in the Tumor Microenvironment and a Vital Regulator of Tumor Biology,” MedComm 4 (2023): e376.

[173] S. Partlová, J. Bouček, K. Kloudová, et al., “Distinct Patterns of Intratumoral Immune Cell Infiltrates in Patients With HPV-Associated Compared to Non-Virally Induced Head and Neck Squamous Cell Carcinoma,” Oncoimmunology 4 (2015): e965570.

[174] X. Zhang, D. Yu, D. Wu, et al., “Tissue-Resident Lachnospiraceae Family Bacteria Protect Against Colorectal Carcinogenesis by Promoting Tumor Immune Surveillance,” Cell Host & Microbe 31 (2023): 418–432. e8.

[175] S. Pushalkar, M. Hundeyin, D. Daley, et al., “The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression,” Cancer Discovery 8 (2018): 403–416.

[176] G. Zhu, H. Su, C. H. Johnson, S. A. Khan, H. Kluger, and L. Lu, “Intratumour Microbiome Associated With the Infiltration of Cytotoxic CD8+ T Cells and Patient Survival in Cutaneous Melanoma,” European Journal of Cancer (Oxford, England: 1990) 151 (2021): 25–34.

[177] D. Sheng, K. Yue, H. Li, L. Zhao, G. Zhao, and C. Jin, “The Interaction Between Intratumoral Microbiome and Immunity Is Related to the Prognosis of Ovarian Cancer,” Microbiology Spectrum 11 (2023): e0354922.

[178] J. F. Anker, A. F. Naseem, H. Mok, A. J. Schaeffer, S. A. Abdulkadir, and P. Thumbikat, “Multi-Faceted Immunomodulatory and Tissue-Tropic Clinical Bacterial Isolate Potentiates Prostate Cancer Immunotherapy,” Nature Communications 9 (2018): 1591.

[179] Z. Zhang, Q. Gao, X. Ren, et al., “Characterization of Intratumor Microbiome in Cancer Immunotherapy,” Innovations (Cambridge, Mass) 4 (2023): 100482.

[180] Z. A. Rizvi, R. Dalal, S. Sadhu, et al., “High-Salt Diet Mediates Interplay Between NK Cells and Gut Microbiota to Induce Potent Tumor Immunity,” Science Advances 7 (2021): eabg5016.

[181] X. Dong, P. Pan, D.-W. Zheng, P. Bao, X. Zeng, and X.-Z. Zhang, “Bioinorganic Hybrid Bacteriophage for Modulation of Intestinal Microbiota to Remodel Tumor-Immune Microenvironment Against Colorectal Cancer,” Science Advances 6 (2020): eaba1590.

[182] C. S. Eberhardt, H. T. Kissick, M. R. Patel, et al., “Functional HPV-Specific PD-1+ Stem-Like CD8 T Cells in Head and Neck Cancer,” Nature 597 (2021): 279–284.

[183] H. Raskov, A. Orhan, J. P. Christensen, and I. Gögenur, “Cytotoxic CD8+ T Cells in Cancer and Cancer Immunotherapy,” British Journal of Cancer 124 (2021): 359–367.

[184] D. Huang, Y. Chen, C. Li, et al., “Variations in Salivary Microbiome and Metabolites Are Associated With Immunotherapy Efficacy in Patients With Advanced NSCLC,” Msystems 10 (2025): e0111524.

[185] Y. Liu, C. C. Wong, Y. Ding, et al., “Peptostreptococcus anaerobius Mediates Anti-PD1 Therapy Resistance and Exacerbates Colorectal Cancer via Myeloid-Derived Suppressor Cells in Mice,” Nature Microbiology 9 (2024): 1467–1482.

[186] J.-C. J. Tsay, B. G. Wu, I. Sulaiman, et al., “Lower Airway Dysbiosis Affects Lung Cancer Progression,” Cancer Discovery 11 (2021): 293–307.

[187] C.-H. Liu, Z. Chen, K. Chen, F.-T. Liao, C.-E. Chung, and X. Liu, “Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-Induced Lung Cancer and Determines the Efficacy of Immunotherapy,” Cancer Research 81 (2021): 144–157.

[188] C. Andolfi, J. C. Bloodworth, A. Papachristos, and R. F. Sweis, “The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness,” Bladder Cancer Amsterdam, the Netherlands 6 (2020): 225–235.

[189] S. Deng, X. Yang, L. He, Y. Hou, and H. Meng, “Tertiary Lymphoid Structures in Microorganism-Related Cancer,” Cancers 16 (2024): 3464.

[190] M. Constantin, M. C. Chifiriuc, G. Mihaescu, et al., “Implications of Oral Dysbiosis and HPV Infection in Head and Neck Cancer: From Molecular and Cellular Mechanisms to Early Diagnosis and Therapy,” Frontiers in Oncology 13 (2023): 1273516.

[191] J. Chen, M. Ren, X. Peng, B. Ren, and L. Cheng, “A Preliminary Study on the Effect of CD47-Targeted Immunotherapy on Oral-Gut Microbiota,” Sichuan Da Xue Xue Bao Yi Xue Ban = Journal of Sichuan University Medical Science Edition 53 (2022): 256–262.

[192] M. He, T. Yang, Y. Wang, et al., “Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy,” Advanced Healthcare Materials 10 (2021): e2002104.

[193] Y. E. Chen, D. Bousbaine, A. Veinbachs, et al., “Engineered Skin Bacteria Induce Antitumor T Cell Responses Against Melanoma,” Science 380 (2023): 203–210.

[194] K. H. Czarnecka-Chrebelska, J. Kordiak, E. Brzeziańska-Lasota, and D. Pastuszak-Lewandoska, “Respiratory Tract Oncobiome in Lung Carcinogenesis: Where Are We Now?,” Cancers 15 (2023): 4935.

[195] Q. Ma, X. Li, H. Jiang, et al., “Mechanisms Underlying the Effects, and Clinical Applications, of Oral Microbiota in Lung Cancer: Current Challenges and Prospects,” Critical Reviews in Microbiology 50 (2024): 631–652.

[196] J. Ma, A. Gnanasekar, A. Lee, et al., “Influence of Intratumor Microbiome on Clinical Outcome and Immune Processes in Prostate Cancer,” Cancers 12 (2020): 2524.

[197] P. Sánchez-Pellicer, C. Boix-Rodríguez, A. Hernández-Belmonte, et al., “Bladder Cancer and Probiotics: What Do We Know So Far?,” Cancers 15 (2023): 5551.

[198] J. Gong, A. Chehrazi-Raffle, V. Placencio-Hickok, M. Guan, A. Hendifar, and R. Salgia, “The Gut Microbiome and Response to Immune Checkpoint Inhibitors: Preclinical and Clinical Strategies,” Clinical and Translational Medicine 8 (2019): 9.

[199] L. Derosa, B. Routy, M. Fidelle, et al., “Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients,” European Urology 78 (2020): 195–206.

[200] C. Zhu, C. Zhang, S. Wang, et al., “Characterizations of Multi-Kingdom Gut Microbiota in Immune Checkpoint Inhibitor-Treated Hepatocellular Carcinoma,” Journal for ImmunoTherapy of Cancer 12 (2024): e008686.

[201] J. A. McCulloch, D. Davar, R. R. Rodrigues, et al., “Intestinal Microbiota Signatures of Clinical Response and Immune-Related Adverse Events in Melanoma Patients Treated With Anti-PD-1,” Nature Medicine 28 (2022): 545–556.

[202] X. Zhu, K. Li, G. Liu, et al., “Microbial Metabolite Butyrate Promotes Anti-PD-1 Antitumor Efficacy by Modulating T Cell Receptor Signaling of Cytotoxic CD8 T Cell,” Gut Microbes 15 (2023): 2249143.

[203] M.-L. Schubert, R. Rohrbach, M. Schmitt, and C. K. Stein-Thoeringer, “The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy,” Frontiers in Immunology 12 (2021): 670286.

[204] M. Wang, F. Yu, and P. Li, “Intratumor Microbiota in Cancer Pathogenesis and Immunity: From Mechanisms of Action to Therapeutic Opportunities,” Frontiers in Immunology 14 (2023): 1269054.

[205] A. Lopès, E. Billard, A. H. Casse, et al., “Colibactin-Positive Escherichia coli Induce a Procarcinogenic Immune Environment Leading to Immunotherapy Resistance in Colorectal Cancer,” International Journal of Cancer 146 (2020): 3147–3159.

[206] H. J. Jang, J. Y. Choi, K. Kim, et al., “Relationship of the Lung Microbiome With PD-L1 Expression and Immunotherapy Response in Lung Cancer,” Respiratory Research 22 (2021): 322.

[207] H. Wang, X. Rong, G. Zhao, et al., “The Microbial Metabolite Trimethylamine N-Oxide Promotes Antitumor Immunity in Triple-Negative Breast Cancer,” Cell Metabolism 34 (2022): 581–594.e8.

[208] M. J. Bender, A. C. McPherson, C. M. Phelps, et al., “Dietary Tryptophan Metabolite Released by Intratumoral Lactobacillus reuteri Facilitates Immune Checkpoint Inhibitor Treatment,” Cell 186 (2023): 1846–1862.e26.

[209] Y. Shi, W. Zheng, K. Yang, et al., “Intratumoral Accumulation of Gut Microbiota Facilitates CD47-Based Immunotherapy via STING Signaling,” Journal of Experimental Medicine 217 (2020): e20192282.

[210] M. Van der Merwe, G. Van Niekerk, A. Botha, and A.-M. Engelbrecht, “The Onco-Immunological Implications of Fusobacterium nucleatum in Breast Cancer,” Immunology Letters 232 (2021): 60–66.

[211] S. Qin, Y. Liu, G. He, et al., “Spatiotemporal Delivery of Dual Nanobodies by Engineered Probiotics to Reverse Tumor Immunosuppression via Targeting Tumor-Derived Exosomes,” ACS Nano 18 (2024): 26858–26871.

[212] C. Feng, P. Tan, G. Nie, and M. Zhu, “Biomimetic and Bioinspired Nano-Platforms for Cancer Vaccine Development,” Exploration Beijing China 3 (2023): 20210263.

[213] K. O'Leary, “FMT for Patients With Cancer,” Nature Medicine 27 (2021): 2057.

[214] X. Li, S. Zhang, G. Guo, J. Han, and J. Yu, “Gut Microbiome in Modulating Immune Checkpoint Inhibitors,” EBioMedicine 82 (2022): 104163.

[215] D. Chen, J. Wu, D. Jin, B. Wang, and H. Cao, “Fecal Microbiota Transplantation in Cancer Management: Current Status and Perspectives,” International Journal of Cancer 145 (2019): 2021–2031.

[216] J. Huang, X. Zheng, W. Kang, et al., “Metagenomic and Metabolomic Analyses Reveal Synergistic Effects of Fecal Microbiota Transplantation and Anti-PD-1 Therapy on Treating Colorectal Cancer,” Frontiers in Immunology 13 (2022): 874922.

[217] W. Zhao, J. Lei, S. Ke, et al., “Fecal Microbiota Transplantation Plus Tislelizumab and Fruquintinib in Refractory Microsatellite Stable Metastatic Colorectal Cancer: An Open-Label, Single-Arm, Phase II Trial (RENMIN-215),” EClinicalMedicine 66 (2023): 102315.

[218] F. Wang, Q. Yin, L. Chen, and M. M. Davis, “Bifidobacterium Can Mitigate Intestinal Immunopathology in the Context of CTLA-4 Blockade,” PNAS 115 (2018): 157–161.

[219] L. F. Mager, R. Burkhard, N. Pett, et al., “Microbiome-Derived Inosine Modulates Response to Checkpoint Inhibitor Immunotherapy,” Science 369 (2020): 1481–1489.

[220] A. Sivan, L. Corrales, N. Hubert, et al., “Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy,” Science 350 (2015): 1084–1089.

[221] L. Shi, J. Sheng, G. Chen, et al., “Combining IL-2-Based Immunotherapy With Commensal Probiotics Produces Enhanced Antitumor Immune Response and Tumor Clearance,” Journal for ImmunoTherapy of Cancer 8 (2020): e000973.

[222] V. Le Noci, S. Guglielmetti, S. Arioli, C. Camisaschi, F. Bianchi, and M. Sommariva, “Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance Against Lung Metastases,” Cell Reports 24 (2018): 3528–3538.

[223] X. Yang, M. Da, W. Zhang, Q. Qi, C. Zhang, and S. Han, “Role of Lactobacillus in Cervical Cancer,” Cancer Management and Research 10 (2018): 1219–1229.

[224] K. Kaźmierczak-Siedlecka, K. Skonieczna-Żydecka, T. Hupp, R. Duchnowska, N. Marek-Trzonkowska, and K. Połom, “Next-Generation Probiotics—Do They Open New Therapeutic Strategies for Cancer Patients?,” Gut Microbes 14 (2022): 2035659.

[225] W. Liu, Z. Pi, and W. Mao, “Beyond Probiotics: Postbiotics Sensitize Cancer Cells to Immune Checkpoint Inhibitors,” Trends in Cancer 10 (2024): 5–7.

[226] M. Messaoudene, S. Ferreira, N. Saint-Lu, et al., “The DAV132 Colon-Targeted Adsorbent Does Not Interfere With Plasma Concentrations of Antibiotics but Prevents Antibiotic-Related Dysbiosis: A Randomized Phase I Trial in Healthy Volunteers,” Nature Communications 15 (2024): 8083.

[227] F. Pederzoli, M. Bandini, D. Raggi, et al., “Is There a Detrimental Effect of Antibiotic Therapy in Patients With Muscle-Invasive Bladder Cancer Treated With Neoadjuvant Pembrolizumab?,” European Urology 80 (2021): 319–322.

[228] C. G. Kim, J.-Y. Koh, S.-J. Shin, et al., “Prior Antibiotic Administration Disrupts Anti-PD-1 Responses in Advanced Gastric Cancer by Altering the Gut Microbiome and Systemic Immune Response,” Cell Reports Medicine 4 (2023): 101251.

[229] L. Eng, R. Sutradhar, Y. Niu, et al., “Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study,” Journal of Clinical Oncology Official Journal of American Society of Clinical Oncology 41 (2023): 3122–3134.

[230] K. S. Cheung, L. K. Lam, W. K. Seto, and W. K. Leung, “Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated With Lower Survival in Hepatocellular Carcinoma,” Liver Cancer 10 (2021): 606–614.

[231] Y. Jing, X. Chen, K. Li, et al., “Association of Antibiotic Treatment With Immune-Related Adverse Events in Patients With Cancer Receiving Immunotherapy,” Journal for ImmunoTherapy of Cancer 10 (2022): e003779.

[232] M. Uribe-Herranz, S. Beghi, M. Ruella, et al., “Modulation of the Gut Microbiota Engages Antigen Cross-Presentation to Enhance Antitumor Effects of CAR T Cell Immunotherapy,” Molecular Therapy, The Official Journal of the American Society of Gene and Cell Therapy 31 (2023): 686–700.

[233] L. Mao, B. Xarpidin, R. Shi, et al., “Natural Enzyme-Loaded Polymeric Stealth Coating-Armed Engineered Probiotics by Disrupting Tumor Lactate Homeostasis to Synergistic Metabolism-Immuno-Enzyme Dynamic Therapy,” Advanced Science (Weinheim, Baden-Württemberg, Germany) 12, no. 16 (2025): e2417172.

[234] E. Abdollahi, T. P. Johnston, Z. Ghaneifar, et al., “Immunomodulatory Therapeutic Effects of Curcumin on M1/M2 Macrophage Polarization in Inflammatory Diseases,” Current Molecular Pharmacology 16 (2023): 2–14.

[235] K. Kiyotani, Y. Toyoshima, and Y. Nakamura, “Personalized Immunotherapy in Cancer Precision Medicine,” Cancer Biology & Medicine 18 (2021): 955–965.

[236] D. A. Braun, G. Moranzoni, V. Chea, et al., “A Neoantigen Vaccine Generates Antitumour Immunity in Renal Cell Carcinoma,” Nature 639 (2025): 474–482.

[237] T. Ye, F. Li, G. Ma, and W. Wei, “Enhancing Therapeutic Performance of Personalized Cancer Vaccine via Delivery Vectors,” Advanced Drug Delivery Reviews 177 (2021): 113927.

[238] D. Ni, S. Qing, H. Ding, et al., “Biomimetically Engineered Demi-Bacteria Potentiate Vaccination Against Cancer,” Advanced Science (Weinheim, Baden-Württemberg, Germany) 4 (2017): 1700083.

[239] V. Papa, T. Schepis, G. Coppola, et al., “The Role of Microbiota in Pancreatic Cancer,” Cancers 15 (2023): 3143.

[240] D. E. Kiousi, A. Z. Kouroutzidou, K. Neanidis, et al., “The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions,” Cancers 15 (2023): 2101.

[241] X. Zhang, X. Qin, and S. Wang, “Commensal Bacteria and Cancer Immunotherapy: Strategy and Opportunity,” Life Medicine 2 (2023): lnad024.

[242] X. Huang, M. Hu, T. Sun, et al., “Multi-Kingdom Gut Microbiota Analyses Define Bacterial-Fungal Interplay and Microbial Markers of Pan-Cancer Immunotherapy Across Cohorts,” Cell Host & Microbe 31 (2023): 1930–1943.e4.

[243] A. Lin, L. Huang, A. Jiang, et al., “Microbiota Boost Immunotherapy? A Meta-Analysis Dives Into Fecal Microbiota Transplantation and Immune Checkpoint Inhibitors,” BMC Medicine [Electronic Resource] 23 (2025): 341.

[244] C. K. Stein-Thoeringer, N. Y. Saini, E. Zamir, et al., “A Non-Antibiotic-Disrupted Gut Microbiome Is Associated With Clinical Responses to CD19-CAR-T Cell Cancer Immunotherapy,” Nature Medicine 29 (2023): 906–916.

[245] Z. Yang, J. Ma, J. Han, et al., “Gut Microbiome Model Predicts Response to Neoadjuvant Immunotherapy Plus Chemoradiotherapy in Rectal Cancer,” Medical New York 5 (2024): 1293–1306.e4.

[246] J. Ma, L. Huang, D. Hu, S. Zeng, Y. Han, and H. Shen, “The Role of the Tumor Microbe Microenvironment in the Tumor Immune Microenvironment: Bystander, Activator, or Inhibitor?,” Journal of Experimental & Clinical Cancer Research CR 40 (2021): 327.

[247] C. Vilanova and M. Porcar, “Are Multi-Omics Enough?,” Nature Microbiology 1 (2016): 16101.

[248] Y. Liu, S. Zhang, K. Liu, X. Hu, and X. Gu, “Advances in Drug Discovery Based on Network Pharmacology and Omics Technology,” Current Pharmaceutical Analysis 21 (2024): 33–43.

[249] Z. Wang, Y. Zhao, and L. Zhang, “Emerging Trends and Hot Topics in the Application of Multi-Omics in Drug Discovery: A Bibliometric and Visualized Study,” Current Pharmaceutical Analysis 21 (2024): 20–32.

[250] C. Wang, L. Zhong, J. Xu, et al., “Oncolytic Mineralized Bacteria as Potent Locally Administered Immunotherapeutics,” Nature Biomedical Engineering 8 (2024): 561–578.

[251] L. A. Emens, P. J. Romero, A. C. Anderson, et al., “Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision,” Journal for ImmunoTherapy of Cancer 12 (2024): e009063.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.